SCHEMBL4716165

SCHEMBL4716165

O=c1ccc2c(ccn2Cc2ccc(F)c(Cl)c2)n1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
ICMT O60725 1/20 0.39
PPARG P37231 1/20 0.38
P2RX7 Q99572 5/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37
MEN1 O00255 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
MAPK3 P27361 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4761608 0.89 MAPT (0.36) P2RX7LMNAPOLBTHRBHTT
SCHEMBL4715863 0.89 CYP3A4 (0.46) POLBMEN1CYP3A4CYP2D6CYP2C9
SCHEMBL4714110 0.86 LMNA (0.44) LMNAPOLBTHRBMEN1HTT
SCHEMBL5124227 0.85 SMN1; SMN2 (0.43) LMNATHRBHTT
SCHEMBL4716315 0.84 ALDH1A1 (0.47) LMNAPOLBTHRBHTTMAPK8
SCHEMBL4713845 0.84 BRD4 (0.46) MEN1CYP2D6HTTKMT2AMAPK8
SCHEMBL4715873 0.80 TP53 (0.46) LMNAPOLBTHRBMEN1CYP2D6
SCHEMBL4711879 0.79 MEN1 (0.41) P2RX7LMNAMEN1HTTKMT2A
SCHEMBL4714560 0.78 CCR2 (0.52)
SCHEMBL5113137 0.78 HTR6 (0.44) LMNACYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US claimed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US claimed
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 PIK3CD 198/4885PIK3CA 184/4885PIK3CB 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.